Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

11 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055 - Follow-Up - Conjunctival Exam; Corneal Exam; Anterior Chamber Exam; Lens Opacity; Fundus Exam; Optical Coherence Tomography; Fundus photographs and fluorescein angiography status

- 09/03/2020 - 1 Formulaire, 7 Groupes Item, 69 Eléments de données, 1 Langue
Groupes Item: Conjunctival Exam , Corneal Exam , Anterior Chamber Exam , Lens Opacity , Fundus Exam , Optical Coherence Tomography , Fundus photographs and fluorescein angiography status
Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration

Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055 - Week 52 - Conjunctival Exam; Corneal Exam; Anterior Chamber Exam; Lens Opacity; Fundus Exam; Optical Coherence Tomography; Fundus photographs and fluorescein angiography status

- 08/03/2020 - 1 Formulaire, 7 Groupes Item, 69 Eléments de données, 1 Langue
Groupes Item: Conjunctival Exam , Corneal Exam , Anterior Chamber Exam , Lens Opacity , Fundus Exam , Optical Coherence Tomography , Fundus photographs and fluorescein angiography status
Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration

Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055 - Week 8; 12; 16; 20; 28; 32; 36; 40; 44; 48 - Conjunctival Exam; Corneal Exam; Anterior Chamber Exam; Lens Opacity; Fundus Exam; Optical Coherence Tomography; Fundus photographs and fluorescein angiography status

- 06/03/2020 - 1 Formulaire, 7 Groupes Item, 69 Eléments de données, 1 Langue
Groupes Item: Conjunctival Exam , Corneal Exam , Anterior Chamber Exam , Lens Opacity , Fundus Exam , Optical Coherence Tomography , Fundus photographs and fluorescein angiography status
Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration

Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055 - Week 4 - Conjunctival Exam; Corneal Exam; Anterior Chamber Exam; Lens Opacity; Fundus Exam; Optical Coherence Tomography; Fundus photographs and fluorescein angiography status

- 02/03/2020 - 1 Formulaire, 7 Groupes Item, 69 Eléments de données, 1 Langue
Groupes Item: Conjunctival Exam , Corneal Exam , Anterior Chamber Exam , Lens Opacity , Fundus Exam , Optical Coherence Tomography , Fundus photographs and fluorescein angiography status
Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration

Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055 - Unscheduled - Conjunctival Exam; Corneal Exam; Anterior Chamber Exam; Lens Opacity; Fundus Exam; Optical Coherence Tomography; Fundus photographs and fluorescein angiography status; Ranibizumab Re-Injection

- 17/02/2020 - 1 Formulaire, 8 Groupes Item, 73 Eléments de données, 1 Langue
Groupes Item: Conjunctival Exam , Corneal Exam , Anterior Chamber Exam , Lens Opacity , Fundus Exam , Optical Coherence Tomography , Fundus photographs and fluorescein angiography status , Ranibizumab Re-Injection
Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration

Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055 - Day 1 - Conjunctival Exam; Corneal Exam; Anterior Chamber Exam; Lens Opacity; Fundus Exam; Optical Coherence Tomography; Fundus photographs and fluorescein angiography status; Randomisation Number; Treatment Regimen; Investigational Product (Eye Drops) - First Dose Date/ Time, Dispensed, Administration

- 14/02/2020 - 1 Formulaire, 12 Groupes Item, 78 Eléments de données, 1 Langue
Groupes Item: Conjunctival Exam , Corneal Exam , Anterior Chamber Exam , Lens Opacity , Fundus Exam , Optical Coherence Tomography , Fundus photographs and fluorescein angiography status , Randomisation Number, Treatment Regimen , Investigational Product (Eye Drops) - First Dose Date/ Time , Investigational Product (Eye Drops) - Dispensed, Eye Drop Administration
Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration

Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055 - Screen - Anterior Chamber Exam; Lens Opacity; Fundus Exam; Optical Coherence Tomography; Fundus photographs and fluorescein angiography status

- 24/01/2020 - 1 Formulaire, 5 Groupes Item, 41 Eléments de données, 1 Langue
Groupes Item: Anterior Chamber Exam, Lens Opacity, Fundus Exam, Optical Coherence Tomography, Fundus photographs and fluorescein angiography status
Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration

medical examination SHIP-Trend-0 Fundus_oculi_OCT2000

- 06/12/2017 - 1 Formulaire, 1 Groupe Item, 6 Eléments de données, 2 Langues
Groupe Item: Fundus_oculi_OCT2000
Fundus_oculi_OCT2000 form of SHIP Study (Study of Health in Pomerania), conducted by the University of Greifswald. SHIP unique domain name SHIP.SHIPTrend0.MEX.PHYSEXAM.AHAOCT. ODM derived from https://www.fvcm.med.uni-greifswald.de/dd_service/data_use_explore.php. Further information: http://www2.medizin.uni-greifswald.de/cm/fv/ship.html.
 Publication granted by Prof. Völzke. Reference: Völzke H, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294-307. PMID: 20167617

medical examination SHIP-Trend-0 Fundus_oculi_Reading_OCT2000

- 15/11/2017 - 1 Formulaire, 1 Groupe Item, 18 Eléments de données, 2 Langues
Groupe Item: Fundus_oculi_Reading_OCT2000
Fundus_oculi_Reading_OCT2000 form of SHIP Study (Study of Health in Pomerania), conducted by the University of Greifswald. SHIP unique domain name SHIP.SHIPTrend0.MEX.PHYSEXAM.AHAREADOCT. ODM derived from https://www.fvcm.med.uni-greifswald.de/dd_service/data_use_explore.php. Further information: http://www2.medizin.uni-greifswald.de/cm/fv/ship.html.
 Publication granted by Prof. Völzke. Reference: Völzke H, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294-307. PMID: 20167617

medical examination SHIP-Trend-0 static fundus analysis (reading data)

- 15/11/2017 - 1 Formulaire, 1 Groupe Item, 18 Eléments de données, 2 Langues
Groupe Item: static fundus analysis (reading data)
static fundus analysis (reading data) form of SHIP Study (Study of Health in Pomerania), conducted by the University of Greifswald. SHIP unique domain name SHIP.SHIPTrend0.MEX.PHYSEXAM.AHAREAD. ODM derived from https://www.fvcm.med.uni-greifswald.de/dd_service/data_use_explore.php. Further information: http://www2.medizin.uni-greifswald.de/cm/fv/ship.html.
 Publication granted by Prof. Völzke. Reference: Völzke H, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294-307. PMID: 20167617

medical examination SHIP-Trend-0 static fundus analysis

- 15/11/2017 - 1 Formulaire, 1 Groupe Item, 6 Eléments de données, 2 Langues
Groupe Item: static fundus analysis
static fundus analysis form of SHIP Study (Study of Health in Pomerania), conducted by the University of Greifswald. SHIP unique domain name SHIP.SHIPTrend0.MEX.PHYSEXAM.AHA. ODM derived from https://www.fvcm.med.uni-greifswald.de/dd_service/data_use_explore.php. Further information: http://www2.medizin.uni-greifswald.de/cm/fv/ship.html.
 Publication granted by Prof. Völzke. Reference: Völzke H, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294-307. PMID: 20167617

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial